<DOC>
	<DOCNO>NCT00275041</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , irinotecan , work different way stop growth tumor cell , either kill cell stop dividing . Monoclonal antibody , cetuximab , block tumor growth different way . Some block ability tumor cell grow spread . Others find tumor cell help kill carry tumor-killing substance . Giving irinotecan together cetuximab may kill tumor cell . PURPOSE : This phase II trial study well give irinotecan together cetuximab work treat patient metastatic breast cancer .</brief_summary>
	<brief_title>Irinotecan Cetuximab Treating Patients With Metastatic Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine antitumor activity , confirm response rate , concurrent irinotecan hydrochloride cetuximab patient metastatic breast cancer prior anthracycline and/or taxane-containing therapy . Secondary - Estimate 6-month , progression-free survival patient . - Evaluate adverse event profile irinotecan hydrochloride combination cetuximab patient metastatic breast cancer . - Estimate progression-free survival patient . - Estimate overall survival . OUTLINE : Patients receive cetuximab IV 1-2 hour day 1 , 8 , 15 irinotecan hydrochloride IV 1½ hour day 1 8 . Courses repeat every 21 day absence disease progression unacceptable toxicity . After completion study treatment , patient follow periodically 5 year . PROJECTED ACCRUAL : A total 38 patient accrue study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm adenocarcinoma breast Clinical manifestation metastatic disease If patient 's tumor HER2 positive ( 3+ immunohistochemistry [ IHC ] amplify fluorescent situ hybridization [ FISH ] ) , must receive least one prior trastuzumab ( Herceptin ) contain regimen unless contraindication Measurable disease define least one lesion whose long diameter accurately measure The evidence metastasis must bone metastasis nonmeasurable disease Nonmeasurable disease define lesion , include small lesion ( long diameter &lt; 2 cm ) truly nonmeasurable lesion include follow : Bone lesion Leptomeningeal disease Ascites Pleural/pericardial effusion Inflammatory breast disease Lymphangitis cutis/pulmonis Cystic lesion Abdominal mass confirm followed imaging technique No know CNS metastasis unless control prior surgery and/or radiotherapy To consider control , must least 2 month symptom evidence progression prior study entry Hormone receptor status Not specify PATIENT CHARACTERISTICS : Men woman Menopausal status specify ECOG performance status 02 Life expectancy &gt; 3 month Hemoglobin &gt; 8.0 g/dL Absolute neutrophil count ≥ 1,500/mm³ Platelet count ≥ 100,000/mm³ Creatinine ≤ 1.5 time upper limit normal ( ULN ) Bilirubin normal AST ALT ≤ 5 time ULN Not pregnant nursing Negative pregnancy test Fertile patient must employ adequate contraception ( determined treat physician ) treatment 30 day treatment end Diseasefree ≥ 3 year invasive nonbreast malignancy ( exception : curatively treat basal cell squamous cell carcinoma skin carcinoma situ cervix ) No history allergy hypersensitivity drug product excipients , murine antibody , agent chemically similar irinotecan and/or cetuximab No history evidence Gilbert 's syndrome No active , unresolved infection No New York Heart Association class III IV cardiovascular disease No serious concomitant medical condition would make undesirable patient participate trial would jeopardize compliance protocol treatment PRIOR CONCURRENT THERAPY : See Disease Characteristics No 2 prior chemotherapy regimen metastatic setting ( irrespective hormonal therapy prior trastuzumab therapy ) Prior treatment metastatic adjuvant setting must include anthracycline taxane No major surgery ≤ 3 week prior registration No chemotherapy ≤ 2 week prior registration No radiotherapy ≤ 4 week prior registration No prior irinotecan hydrochloride No prior therapy epidermal growth factor receptor ( EGFR ) antagonist ( either monoclonal antibody tyrosine kinase inhibitor ) , gefitinib erlotinib No prior therapy dual EGFR/HER2 inhibitor ( e.g. , lapatinib ) No concurrent interleukin11 ( oprelvekin ) Routine use granulocyte colony stimulate factor ( CSFs ) permit course 1 study Subsequent use CSFs permit discretion treat investigator No concurrent antitumor therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>recurrent breast cancer</keyword>
	<keyword>stage IV breast cancer</keyword>
	<keyword>male breast cancer</keyword>
</DOC>